Nov 11 2010
Argos Therapeutics has declared that Fred Miesowicz, COO and VP of Manufacturing, will participate in the Cell Therapy Industry Summit-2010, which will be held at the Sheraton Carlsbad Resort and Spa, California and will offer a presentation on the ‘implementation, cost effectiveness and benefits of automation for Argos' Arcelis immunotherapy.’
The company recently proclaimed affirmative interim outcomes of the second phase clinical investigation of the Arcelis immunotherapy, combined with sunitinib, for treating renal cell carcinoma (RCC). It was reported that the company is determined to go ahead t with the phase 3 clinical experiments and execute its automation procedure before commercialization, thereby enabling the company to quickly deal with the medical requirements of the entire targeted RCC patients.
Source: http://www.argostherapeutics.com